Evaluation and Management of a Skin Lesion on the Temple
For any skin lesion on the temple, perform a biopsy or aspiration early to obtain material for histological and microbiological evaluation, as this is the critical first diagnostic step that determines all subsequent management 1.
Initial Diagnostic Approach
The temple region presents unique challenges due to its anatomical complexity, proximity to critical structures (nerves, vessels), and cosmetic significance. The differential diagnosis is broad and includes:
Benign Lesions
- Seborrheic keratosis (may present as red-brown plaques with vascular patterns and melanophages) 2
- Actinic keratosis
- Benign appendage tumors
- Neurofibromas (rare, but can occur in this region) 3
Malignant Lesions
- Basal cell carcinoma (BCC) - most common
- Squamous cell carcinoma (SCC) - high-risk location
- Melanoma - requires specific staging considerations
- Primary cutaneous lymphomas (rare)
Infectious Causes (in immunocompromised patients)
- Bacterial (including Nocardia)
- Fungal (Aspergillus, Cryptococcus, Mucormycosis)
- Viral (VZV, HSV)
Key Clinical Features to Document
Examine and record:
- Size and margins: Well-defined vs ill-defined borders
- Color changes: Pigmentation patterns, vascular patterns (hairpin vessels suggest seborrheic keratosis)
- Texture: Raised, flat, ulcerated, crusted
- Growth pattern: Rapid vs slow, recent changes
- Associated symptoms: Pain, bleeding, pruritus
- Patient factors: Immunosuppression status, prior skin cancers, sun exposure history
Biopsy Technique Selection
For suspected malignancy, perform complete/excisional biopsy with 1-3mm margins using full-thickness technique (fusiform/elliptical, disk, or punch) or deep shave into reticular dermis 4. This maximizes histopathologic examination and microstaging.
Pathology Report Must Include (for malignancy):
- Breslow depth (for melanoma)
- Ulceration status
- Mitotic rate
- Histologic subtype
- Margin status
- Lymphovascular invasion
Management Based on Diagnosis
For Basal Cell Carcinoma
The temple is a high-risk location requiring Mohs micrographic surgery as the preferred treatment, achieving 99% 5-year cure rates for primary tumors and 94.4% for recurrent disease 5.
Indications for Mohs surgery on temple lesions:
- All facial BCCs in high-risk locations (temple qualifies)
- Recurrent tumors
- Aggressive histologic subtypes (infiltrative, morpheaform, micronodular)
- Tumors >2cm
- Ill-defined clinical margins
Alternative for low-risk, small (<2cm), well-defined nodular BCC: Surgical excision with minimum 4mm margins achieves 95% complete removal 6. However, given the temple's high-risk status, wider margins (6mm or more) with histologic examination are preferable.
For Squamous Cell Carcinoma
Temple location is high-risk for SCC due to increased metastatic potential and aggressive behavior 6.
Surgical excision with minimum 6mm margins (or wider) with histologic margin assessment is required for high-risk locations like the temple 6. Mohs surgery is strongly preferred for:
- Tumors >2cm
- Poorly differentiated (Broders' grade 2-4)
- Recurrent lesions
- Subcutaneous extension
For Melanoma
Complete excisional biopsy is mandatory first step 4. Wide excision margins depend on Breslow depth:
- In situ: 0.5-1cm margins
- ≤1mm: 1cm margins
- 1.01-2mm: 1-2cm margins
2mm: 2cm margins
Sentinel lymph node biopsy should be performed at time of wide excision for appropriate tumor thickness with other high-risk features 4.
For Immunocompromised Patients
If the patient is immunocompromised (chemotherapy, transplant, immunosuppressive drugs), immediately consider dermatology consultation and obtain skin biopsy for both routine histology AND cultures (bacterial, fungal, viral) 1, 7, 1.
Empiric therapy while awaiting cultures:
- Bacterial coverage: Vancomycin 30-60mg/kg/day (target trough 15-20 μg/mL) 7
- Fungal coverage: Voriconazole (6mg/kg IV q12h × 2 doses, then 4mg/kg q12h) 7
- Viral coverage: IV acyclovir for suspected HSV/VZV 1
Critical Pitfalls to Avoid
Never treat temple lesions with narrow margins or destructive techniques without histologic confirmation - the temple's high-risk status and proximity to critical structures demands tissue-sparing yet complete excision
Do not assume clinical margins accurately predict tumor extent - microscopic extension is common, especially in aggressive subtypes 6
In immunocompromised patients, do not delay biopsy - seemingly innocuous lesions may represent life-threatening disseminated infections 1
Avoid curettage and cautery for facial/temple lesions - associated with 47% residual tumor rate on head and neck sites 5
Do not perform partial/shave biopsies for pigmented lesions - inadequate for Breslow depth measurement critical for melanoma staging 4